Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Investor Presentation (August 2022)
19 slides from Nova Eye Medical's investor presentation, Aug 26, 2022
Slide 1: FY22 Full-Year Results Presentation
Nova Eye Medical Limited (ASX:EYE) FY22 Full-Year Results Presentation 25 August 2022
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: FY22 Achievements
FY22 ACHIEVEMENTS The 2022 financial year saw us expand the depth of our operations in the Glaucoma Surgical Consumable Device segment, achieving a series of commercial, market access, product development and clinical goals. Achieved production- Acquired seminal Successfully navigated Continued to i
Slide 4: Glaucoma Market Strong Global Growth Theme
Glaucoma Market Strong Global Growth Theme Glaucoma is the leading cause of irreversible blindness. The aging global population drives prevalence, representing a significant opportunity for our global business. Western US$610m Europe CAGR 17% USA Glaucoma Surgical XX% Device market size China 134.2
Slide 5: Glaucoma Technology Portfolio and Pipeline
Glaucoma Technology Portfolio and Pipeline We continue to invest in a comprehensive portfolio of glaucoma technologies that span the entire glaucoma treatment algorithm, underpinned by our robust R&D and IP pipeline. STAGE OF GLAUCOMA Mild Glaucoma Moderate Glaucoma Severe Glaucoma Complex Glaucoma
Slide 6: iTrack Advance
• The new iTrack™ Advance is an injector deployed microcatheter, leveraging the effectiveness, accuracy and reliability of the original iTrack™. • iTrack™ Advance combines a microcatheter with an ergonomic, easy-to-use handheld injector designed for all ophthalmic surgery and specialists settings. •
Slide 7: The new iTrack Advance will appeal to existing surgeon customers
200 1,2001 The new iTrack™ Advance will appeal to existing surgeon estimated glaucoma customers surgeon market Cataract surgeons as well as Glaucoma surgeons, expanding the total addressable market by c.10x. In the USA, iTrack™ is regularly used by approximately 200 specialist glaucoma surgeons. The
Slide 8: Surgeon testimonials on canaloplasty and iTrack Advance
“There is enough data to support the use of canaloplasty for early glaucoma. What’s more, this device can truly pressurize the canal. The new iTrack™ Advance does not “iTrack™ Advance is my go-to MIGS procedure. have the overhead of requiring a The handpiece offers improved efficiency, which will se
Slide 9: Important FY22 Activities
Important FY22 Activities • Global Clinical Team (outside the USA) training • Reimbursement strategy in place to support sales to surgeons in Germany, the UK, Italy, Spain, Poland, cataract surgeons and comprehensive Canada and Australia. ophthalmologists. • Surgical training roll-out to top tier gl
Slide 10: European Market Update
European Market Update Financial Performance: Strong German sales during the period, up 24% on the prior period. Today, Germany accounts for 17% of total global sales. • Positive sales momentum underscored by the launch of iTrack™ Advance. • Comprehensive clinical and surgical training program launc
Slide 11: USA Market Update
USA Market Update Financial Performance: Sales revenue was down 3% on the prior period. This followed a strong rebound during the 6 months to 30 June 2022 in which sales grew 10%, compared with sales in the 6 months to 31 December 2021. Positive turnaround in sales of our legacy iTrack™ device is at
Slide 12: FY22 Glaucoma Operating Result
FY22 Glaucoma Operating Result A $'000’s1 US $'000’s¹ Geographic sales composition: FY21 FY22 FY21 FY22 Sales composition using Sales 13,088 13,137 9,684 9,534 US$: USA 67% (pcp 68%), Western Europe 28% (pcp COGS2 (4,473) (5,123) (3,310) (3,703) 24%), China 5% (pcp 7%) Gross Margin 8,615 8,014 6,374
Slide 13: 2RT is a proprietary, world-first nanosecond laser therapy
• Age-related macular degeneration (AMD) is the leading cause of blindness in industrialized countries in people over the age of 50 years. • While there have been major advances in the treatment of AMD in its late stages 2RT® is a proprietary, world-first (referred to as Wet AMD), there has been lit
Slide 14: 2RT Development Milestones
2RT® Development Milestones Our current strategy for 2RT® is to undertake a confirmatory pivotal clinical study at sites in Europe, Australia, Canada and ultimately the USA to gain FDA clearance for the treatment of intermediate AMD funded by partners. ✓ PRE-CLINCAL WORK Completed Investigational De
Slide 15: 2RT for Intervention in AMD Progression
2RT® for Intervention in AMD Progression Intervention concept schematic based on a post hoc analysis reported within “Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration - The LEAD Randomized Controlled Clinical Trial” Robyn H. Guymer, MBBS, PhD, et al and published in pee
Slide 16: Nova Eye Group Outlook
Nova Eye Group Outlook • Investments in the 2022 financial year and the European launch of iTrack™ Advance will trigger sales growth of the Glaucoma Surgical Consumable Device segment in the 2023 financial year. • Subject to the continuation of current market conditions, sales for the four months to
Slide 17: Financials and Corporate Snapshot
ASX: EYE Financials and Corporate Snapshot Australian Securities EYE 7% Exchange Ticker Management + Board Exchange Ownership Nova Eye Medical Limited 146M A$13.1M A$30.4M Shares on Issue Revenues Net Assets (12 months 30 June 2022) (as at 30 June 2022) A$35M A$8.0M Market Capitalisation Cash (as at
Slide 18: Business Snapshot
ASX: Eye Business Snapshot Nova Eye Medical Limited (ASX:EYE) comprises two business units, Glaucoma and AMD/2RT® – these segments address the leading causes of blindness in the developed world. Nova Eye Medical, Glaucoma AlphaRET, AMD Develop, market and sell comprehensive portfolio Strategy Progre
Slide 19: Contact details
Limite Medic Nova Eye al d Tom Spurling Mark Flynn Kate Hunt Managing Director Investor Relations Chief Commercial Officer M: +61 417 818 658 M: +61 416 068 733 M: +61 404 080 679 E: tspurling@nova-eye.com E: mflynn@nova-eye.com E: khunt@nova-eye.com
Nova Eye Medical — Investor Presentation (August 2022) on 6ix